source
- Merck's sac-TMT shows promise in Chinese Phase 3 lung cancer trial, may replace chemoMerck and its Chinese partner Kelun-Biotech reported that the antibody-drug conjugate sac-TMT slowed disease progression better than a standard chemotherapy regimen in a Phase 3 trial conducted in…
- J&J shares fall 3% as oncology sales miss forecasts, while AstraZeneca invests $600M in lung cancer drugJohnson & Johnson’s stock slipped about 3% on Wednesday even though the company raised its full‑year sales outlook. In its latest quarterly earnings release the firm said revenue in its innovative…